UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia
NCT ID: NCT01325298
Last Updated: 2011-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
250 participants
INTERVENTIONAL
2011-03-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
NCT01143389
Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light
NCT05027295
Higher Irradiance in Keratoconus Ectasia
NCT01789333
Corneal Crosslinking in Keratoconus and Corneal Ectasia
NCT00679666
The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy
NCT01106274
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
20 Minute UV-X Light Treatment Duration
20 Minute UV-X Light Treatment Duration
Note: "UV-X" is the trademark of Peschke GmbH
UV-X Light
UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
Riboflavin
Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
30 Minute UV-X Light Treatment Duration
30 Minute UV-X Light Treatment Duration
UV-X Light
UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
Riboflavin
Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UV-X Light
UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
Riboflavin
Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
UV-X Light
UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
Riboflavin
Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ii. Signed, dated, written informed consent
iii. Having documented ectasia on topography or tomography after previous refractive surgery OR progressive keratoconus defined as one or more of the following changes over a period of 24 months or less before randomization:
* An increase of at least 1.0 diopter in the steepest keratometry value (or sim K), or
* an increase of at least 1.0 diopter in regular astigmatism evaluated by subjective manifest refraction, or
* a myopic shift (decrease in the spherical equivalent) of at least 0.5 diopters on subjective refraction, or
* documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia
iv. Have minimal preoperative corneal thickness of 375 microns or more, as measured in the office with epithelium not yet removed
v. For subjects with non-post refractive surgery keratoconus diagnosis only:
* 14 years or older to 55 years of age,
* axial topography consistent with keratoconus such as presence of abnormal central or paracentral steepening on the corneal topography map, or presence of one or more slit lamp findings associated with keratoconus, such as
* Fleischer ring
* Vogt striae
* Corneal thinning
* Corneal scarring
vi. For contact lens wearers only:
Removal of contact lenses for the required period of time prior to final screening refraction:
* Contact lens minimum discontinuation time two weeks for soft, extended wear, soft toric, and rigid gas permeable lenses
vii. For patients with post-refractive surgery keratectasia:
* History of excimer laser refractive surgery with increasing refractive astigmatism and corneal topographic or keratometric astigmatism of 0.5 or more, or a history of decreasing best spectacle corrected visual acuity associated with the presence of topography suggestive of keratoconus or pellucid marginal degeneration or abnormal higher order aberrations (especially coma) on the aberration mapping of the eye.
viii. For patients with corneal transplants:
* History of corneal transplant for keratoconus with documented increasing refractive astigmatism and corresponding topographic irregularity occurring at least one year after corneal transplantation, not attributable to transplant suture removal and occurring during the most recent two years.
Exclusion Criteria
ii. Keratometric readings greater than 62D
iii. No evidence of keratoconus/keratectasia progression over the prior three years
iv. Age less than 55 years but under
* 14 years for keratoconus patients
* 18 years for post-refractive surgery keratectasia and post-transplant patients
v. Previous ocular condition in the eye(s) to be treated that might, in the investigator's opinion, predispose to complications (such as history herpes simplex keratitis, corneal melt, perforated corneal ulcer, descemetocele, prior corneal damage from chemical injury, herpes zoster keratitis, nystagmus, corneal scarring that significantly impairs vision, pre-existing glaucoma, glaucoma suspect, Goldmann applanation pressure exceeding 23 mm Hg, cataract, history of uveitis, active ocular disease that might lead to infection, corneal endothelial cell count below 1800 cells per square millimeter)
vi. Patients with a systemic condition that, in the investigator's opinion, might predispose to complications (such as Down syndrome, autoimmune disease, pregnancy or nursing at the time of initial treatment, history of alcohol abuse, being immunocompromised, allergy to riboflavin or other study medications)
vii. Patients who are unwilling or unable to comply with the study regimen and doctor's advice
viii. Patients unwilling to discontinue wear of rigid contact lenses in the eye to be operated on for at least one month before baseline examination, and for the first six months post-operatively
ix. Patient unwilling to discontinue contact lenses prior to baseline exam: one week for soft lenses, two weeks for rigid or soft toric lenses
x. Pregnancy at the time of proposed crosslinking
xi. Known hypersensitivity to riboflavin
xii. Central corneal endothelial cell count below 1400 cells per square millimeter.
xiii. Presence of significant central corneal stromal scar
xiv. History of delayed wound healing
xv. Immunocompromised patient
xvi. History of connective tissue disease (such as systemic lupus erythematosus, rheumatoid arthritis)
xvii. History of glaucoma, a Goldmann applanation pressure measured in keratoconus evaluation of above 24, or glaucoma suspect, xviii. Significant existing cataract
xix. Macular degeneration or confluent drusen of Bruchs membrane
xx. Evidence of past or present herpes simplex of the cornea
14 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mercy Center for Corrective Eye Surgery
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mercy Center for Corrective Eye Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert L Epstein, MD
Role: PRINCIPAL_INVESTIGATOR
Mercy Center for Corrective Eye Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Center for Corrective Eye Surgery
McHenry, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. Am J Ophthalmol. 2010 Apr;149(4):585-93. doi: 10.1016/j.ajo.2009.10.021. Epub 2010 Feb 6.
Goldich Y, Marcovich AL, Barkana Y, Avni I, Zadok D. Safety of corneal collagen cross-linking with UV-A and riboflavin in progressive keratoconus. Cornea. 2010 Apr;29(4):409-11. doi: 10.1097/ICO.0b013e3181bd9f8c.
Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5. doi: 10.3928/1081597X-20080901-15.
Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039.
Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5. doi: 10.1177/112067210601600405.
Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45. doi: 10.1016/j.jcrs.2006.01.091.
Related Links
Access external resources that provide additional context or updates about the study.
Educational material in website of Mercy Center for Corrective Eye Surgery
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IND 109752
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.